Bruker Co. (NASDAQ:BRKR – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the twelve research firms that are covering the company, MarketBeat Ratings reports. Five analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $74.45.
Several research firms have weighed in on BRKR. UBS Group assumed coverage on Bruker in a research report on Tuesday, December 10th. They issued a “neutral” rating and a $66.00 target price for the company. Wells Fargo & Company dropped their price objective on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a report on Wednesday, November 6th. Bank of America increased their target price on shares of Bruker from $78.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, December 13th. TD Cowen decreased their price target on shares of Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a research report on Wednesday, November 6th. Finally, Wolfe Research lowered Bruker from an “outperform” rating to a “peer perform” rating in a research report on Monday, September 30th.
Read Our Latest Research Report on Bruker
Bruker Price Performance
Bruker (NASDAQ:BRKR – Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). Bruker had a return on equity of 21.52% and a net margin of 9.41%. The firm had revenue of $864.40 million for the quarter, compared to analyst estimates of $866.46 million. During the same quarter last year, the company earned $0.74 earnings per share. The firm’s revenue for the quarter was up 16.4% on a year-over-year basis. As a group, equities research analysts expect that Bruker will post 2.4 earnings per share for the current year.
Bruker Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 16th. Stockholders of record on Monday, December 2nd were given a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, December 2nd. This represents a $0.20 annualized dividend and a dividend yield of 0.35%. Bruker’s dividend payout ratio is currently 9.62%.
Insider Activity
In other news, CEO Frank H. Laukien bought 100,000 shares of the business’s stock in a transaction dated Monday, November 18th. The shares were acquired at an average price of $50.14 per share, for a total transaction of $5,014,000.00. Following the completion of the transaction, the chief executive officer now owns 38,439,563 shares of the company’s stock, valued at approximately $1,927,359,688.82. This trade represents a 0.26 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 28.30% of the company’s stock.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the company. True Wealth Design LLC raised its stake in Bruker by 4,636.4% during the 3rd quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock valued at $36,000 after acquiring an additional 510 shares during the last quarter. UMB Bank n.a. grew its stake in Bruker by 115.3% in the 3rd quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 354 shares during the last quarter. Eagle Bay Advisors LLC increased its stake in shares of Bruker by 2,324.1% during the 4th quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company’s stock worth $41,000 after purchasing an additional 674 shares in the last quarter. Gordian Capital Singapore Pte Ltd acquired a new position in shares of Bruker in the second quarter worth $52,000. Finally, GAMMA Investing LLC lifted its holdings in Bruker by 81.0% in the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock valued at $60,000 after purchasing an additional 388 shares in the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.
Bruker Company Profile
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
See Also
- Five stocks we like better than Bruker
- Most Volatile Stocks, What Investors Need to Know
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- Stock Market Sectors: What Are They and How Many Are There?
- 3 Buy-and-Hold Stocks for Long-Term Growth
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.